




stragen

HEALTH PRODUCTS DEVELOPMENT 

**CORPORATE
BROCHURE**

CONTENT

FEW WORDS	5
LOGO & IDENTITY	7
FACTS & FIGURES	9
A WORLDWIDE PRESENCE	11
BUSINESS UNITS	13
 Rx PRODUCTS	15
 HEALTH CARE INNOVATION	19
 ORIGINAL DRUGS DEVELOPMENT	23
THE READY-TO-USE MARKETING KIT	27
CONTACT	29

FEW WORDS



What a journey it has been... From a small API trading platform in the early 90', STRAGEN is about to reach its 30's year of existence and is now a global player in the development of generics, consumer health and new drugs. Our independence & entrepreneurial philosophy remain our key drivers in everything we do. Consumption and distribution models are changing and the next years will see an acceleration of this phenomenon for which companies have to be ready for. We see these changes as very positive and exciting for our future. Thus, we continuously work to adapt our business model and product offer to meet these new challenges.



Jan TETARD
Executive Vice President

stragen

HEALTH PRODUCTS DEVELOPMENT 



**HEALTH CARE
INNOVATION**

Rx PRODUCTS

**ORIGINAL DRUGS
DEVELOPMENT**

OUR NEW BRAND IDENTITY

It is time for STRAGEN to enter in a new era!

Growing portfolio, rising customer expectations, new traceability requirements, permanent stimulation of innovation, search for new opportunities constitute essential elements where we need continuous renewal.

Our visual identity is naturally part of this evolution.

You will find here the cornerstones of our new brand identity, more flexible and engaging, based on our corporate culture: **entrepreneurial, approachable, innovator.**

It reaches out to all audiences and its original typography invokes **openness and connection.**

The logo has adopted a rich palette of stimulating colors and has been adapted for the different STRAGEN business units.




SWISS COMPANY & QUALITY

Our Swiss expertise and presence are continuously spread out around the world through dedicated affiliates and key partnerships in more than 60 countries.

STRAGEN specialized scientific team constantly operates under the latest quality standards to develop health solutions for tomorrow's needs. **In all we do, we strive to be innovative, reliable and passionate.**

Being a STRAGEN partner means building a close and long-term collaboration and getting part of a dynamic and committed team!



- 
- **150+** employees
 - **10** worldwide affiliates
 - **550+** market authorizations
 - **2** original molecules
 - **4** products under development
 - **60+** operating countries



A WORLDWIDE PRESENCE

STRAGEN aims to provide **Swiss quality products** around the world and spreads its international presence through its affiliates and network of exclusive partners. STRAGEN affiliates benefit from **more than 10 years' experience** in hospital supply of prefilled syringes, injectable antibiotics and oncology products.

Because women's health requires a special attention, STRAGEN has devoted efforts since 15 years to develop contraceptives and recently focused on the development of tailor-made solutions for each stage of women's life. Thanks to its affiliates dedicated to Women's Health, STRAGEN aspires to become an expert in this field by developing **skilled teams of medical representatives** targeting the Gyn specialists.





EXPERTISE

INNOVATION

HEALTH

From the fundamental research to the delivery of **innovative and trusted solutions**, we focus on 3 core activities:

- Selected & advanced generics,
- Consumer health, and
- Original drugs.





stragen

Rx PRODUCTS

When the generic drug market is often synonym of blockbuster race and cost cutting, STRAGEN has always been engaged in the development of **Selected and Advanced Generics**.

Thanks to our **30-year R&D know-how**, we constantly aim at improving the existing therapeutics by offering:

- Niche molecules,
- Hard-to-make drugs,
- Innovative delivery forms to improve health daily practices.





**NOWADAYS, THIS PHILOSOPHY
ALLOWS US TO COVER SPECIFIC
THERAPEUTIC AREAS SUCH AS
ANTI-INFECTIVES, CARDIOLOGY,
ONCOLOGY, ORAL CONTRACEPTION.**



GYNAECOLOGY 

CARDIOLOGY 

HORMONE
DISORDERS 

ONCOLOGY 

PHLEBOLOGY 



ANTI-INFECTIVES 

EPILEPSY 

HAEMORRHAGE 

CARDIOLOGY 

GYNAECOLOGY 

ONCOLOGY 



ANTI-INFLAMMATORY 

DERMATOLOGY 



stragen

HEALTH CARE INNOVATION

Today's consumers are more and more socially connected and digitally educated on the need for healthier lifestyles. Because they are concerned about preserving their health, they are taking an active role in their treatment selection, **looking for scientifically supported solutions** and not only marketing concepts.

We, at STRAGEN, are striving to be leader in the Consumer Health industry by continuously innovating in product development to answer unmet consumer needs.

Our Health Care Innovation range encompasses scientifically selected actives to always offer unique and natural formulas supported by clinically proven efficacy.



**OUR PRODUCTS' STORIES RESONATE
WITH CONSUMERS OWN BELIEFS
WHILE REMAINING ENDORSED
BY HEALTH CARE SPECIALISTS.**



PREGNANCY & INFANT HEALTH

ELLOVA®



IODACIF



INTIMATE HEALTH

ENDELLIA



GYNEVIA



HEALTHY AGEING

ESTROFREE-100®



MENOTROFY



SKIN & VENOUS DISORDERS

ELACNIA



DIOSMIN 95®



IMMUNE & METABOLIC DISORDERS

LEVIKER®



SNIZTOP®





stragen

ORIGINAL DRUGS DEVELOPMENT

ORIGINAL DRUGS DEVELOPMENT

In its continuous commitment to advancing public health, STRAGEN invests in the development up to **proof of concept of patented new drugs** addressing orphan diseases or unmet medical needs.

STRAGEN is honored to partner with biotechnology start-ups, renowned health institutes and innovative stakeholders such as the Institut Pasteur, the Cystic Fibrosis Foundation and BPI France who recognized the unique innovative approach and therapeutic potential of its drug candidates and support their development.





WE TRULY BELIEVE STRAGEN'S ASPIRATIONS WILL PAVE THE WAY FOR PATIENTS TO BENEFIT FROM THESE DISCOVERIES.



ALX-009 CYSTIC FIBROSIS

ALX-009 is developed by the biotechnology start-up Alaxia in which STRAGEN acquired a significant stake in 2011.

ALX-009 is an innovative First-in-Class orphan drug combination of two endogenous substances administered by inhalation. ALX-009 is addressing a strong unmet medical need, targeting multidrug-resistant (MDR) bacterial infections not treatable by current antibiotic therapies by contributing to the lung's innate immune system response.

2018: Phase I - First-in-Man clinical trials including Cystic Fibrosis patients. Evaluation of safety and tolerability of ALX-009 and its constituents.

2019: Start of Phase IIa - Proof of Concept in Cystic Fibrosis (multidrug-resistant infections in adults).

To find out more
about STRAGEN
Original Drugs
contact us at
info@stragen.ch



WE TRULY BELIEVE STRAGEN'S ASPIRATIONS WILL PAVE THE WAY FOR PATIENTS TO BENEFIT FROM THESE DISCOVERIES.



STR-324 PAIN

STR-324 is a First-in-Class non-opioid painkiller with a safe and non-addictive profile and innovative mode of action. Enkephalins are strong endogenous analgesic peptides that are quickly inactivated by peptidases NEP and APN. STR-324 is the synthetic equivalent of the natural human peptide inhibiting the degradation of enkephalin and thus amplifying their strong analgesic potential. Due to its unique mode of action, no opioid-like side effects are expected. Phase I study on healthy volunteers demonstrated that single doses of STR-324 are well tolerated with no significant side effects on any kind.

2018: Phase I - First-in-Man clinical trial to evaluate the safety and tolerability of single and multiple doses of STR-324.

2019: Phase IIa - Proof of Concept in post-operative pain.

2020: Phase IIa - Proof of Concept in neuropathic pain.



The ready-to-use MARKETING KIT

by STRAGEN

- A comprehensive educational concept for doctors and pharmacists
- Digital insights for a closer dialogue with consumers
- A tailor-made approach for a successful partnership

Being a STRAGEN partner means benefit from our B2C expertise in terms of: scientific approach, product positioning, ready-to-use marketing kit and women's health experience.



SCIENTIFIC FILES

TRAINING MATERIALS

VIDEOS

MEDICAL EVENTS & CONGRESSES

To **train** your sales force
To **convince** your target
To **create** brand awareness

IN-STORE VISIBILITY

SUPPORT FROM KOL

E-VISUAL AIDS

SOCIAL MEDIA

PRODUCT WEBSITE

**STRAGEN FRANCE S.A.S.**

Bâtiment Adénine, 60 avenue Rockefeller
69008 Lyon - France
tel +33 4 82 53 75 82
fax +33 4 82 53 32 25
contact@stragen.fr
www.stragen.com

STRAGEN SERVICES S.A.S.

52 rue de la République
69002 Lyon - France
tel +33 4 78 42 95 26
fax +33 4 78 42 55 71
Pharmacovigilance services:
pharmacovigilance@stragen.com
Clinical affairs services:
medaffairs@stragen.com
www.stragen-services.fr

**STRAGEN UK Ltd.**

Castle Court, 41 London Road
Reigate, Surrey RH2 9RJ - United Kingdom
tel +44 1737 735029
info@stragenuk.com
www.stragenuk.com

**STRAGEN PHARMA GmbH**

Eupener Strasse 135-137
50933 Köln - Germany
tel +49-221-5716 4600
fax +49-221-5716 4610
info@stragen-pharma.de
www.stragen.de

**STRAGEN NORDIC A/S**

Helsingørsgade 8 C
3400 Hillerød - Denmark
tel +45 48 10 88 10
info@stragen.dk
www.stragen.dk

**STRAGEN FINLAND OY**

Regus Business Centre Graniittitalo
Jaakonkatu 3B, 7th floor
00100 Helsinki - Finland
tel +358 45 159 2554
info@stragen.fi
www.stragen.fi

**STRAGEN CANADA Inc.**

1140 - 3280 Bloor Street West
11th Floor, Centre Tower
Toronto, ON, Canada, M8X 2X3
tel +1 416 207 2072
www.stragen.ca

**STRAGEN FARMA Ltda.**

Rua Alvorada 1289, 19^o andar, Vila Olimpia
São Paulo - SP, CEP 04550-004 - Brazil
tel +55 11 3372 50 50
sac@stragen.com.br
www.stragen-br.com

**STRAGEN DAROU Co.**

4th floor , N. 82, 31st Ebne Sina St.,
Yousef Abad, Zip code: 1433863596
Tehran - Iran
tel +9821 88 72 80 85
fax +9821 88 10 69 63
info@stragendarou.com
www.stragendarou.com

**STRAGEN PHARMA THAILAND Co., Ltd.**

No. 191 Silom Complex Building
17th Floor, Unit No. 1701
Silom Road, Silom, Bangrak
Bangkok 10500 - Thailand
tel + 66 2 683 3553
fax + 66 2 683 3554
www.stragen.com

**STRAGEN PHARMA S.A. VIETNAM**

Suite 12
67 Le Loi, Ben Nghe, District 1
Ho Chi Minh - Vietnam
tel +84 (28) 73028110
www.stragen.vn

stragen

HEALTH PRODUCTS DEVELOPMENT 

STRAGEN PHARMA SA

Chemin du Pré-Fleuri 3
1228 Plan-les-Ouates / Geneva
Switzerland
tel +41 22 799 19 19
fax +41 22 799 19 99
info@stragen.ch
www.stragen.com

All product related information (including but not limited to therapeutic indications), trademarks, brand names and trade-dress provided herein are used by STRAGEN mainly for B2B purposes, and are the sole property of STRAGEN or under exclusive license. Any use of trademarks or brand names or trade-dress stated herein requires a prior written agreement from STRAGEN.

MEET US AT CPhI 2019

STRAGEN

is pleased to meet you each year at the CPhI Worldwide®.



SAVE THE NEXT DATE:
5-7 NOVEMBER 2019
FRANKFURT, GERMANY

CORP_MAIL_1118_04

stragen

STRAGEN PHARMA SA
Chemin du Pré-Fleuri 3 1228 Plan-les-Ouates/Geneva Switzerland
tel +41 22 799 19 19 fax +41 22 799 19 99 info@stragen.ch www.stragen.ch

